Also, non-gatekeeper mutations such as L1152R, C1156Y, and G1269A, were proposed to be associated with resistance to inhibitors used in the treatment of ALK+ NSCLC [5–7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.